MatthewIMilowskyMD

Genitourinary Oncology

Professor of Medicine, Vice Chief of Research, Section Chief, Genitourinary Oncology, Division of Oncology and Co-Director, Urologic Oncology Program, UNC Lineberger Comprehensive Cancer Center

Join to view full profile

Dr. Milowsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Milowsky's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-0000

Fax+1 919-843-6949
Is this information wrong?

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1999 - 2002
Tufts Medical CenterResidency, Internal Medicine, 1996 - 1999
State University of New York Downstate Medical Center College of MedicineClass of 1996

Certifications & Licensure

NC State Medical License 2011 - 2025
NY State Medical License 1999 - 2013
American Board of Internal Medicine Medical Oncology

Clinical Trials

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma Start of enrollment: 2008 Jul 01
Terminated
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 2
Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer Start of enrollment: 2012 Jul 24
Completed
Not Applicable
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
Completed
Phase 2
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Start of enrollment: 2013 Jun 01
Active, not recruiting
Phase 2
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2014 Jan 23
Completed
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer Start of enrollment: 2013 Oct 01
Terminated
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy Start of enrollment: 2016 May 01
Active, not recruiting
Phase 2
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Start of enrollment: 2017 Aug 24
Active, not recruiting
Phase 2
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Start of enrollment: 2020 Sep 23
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31].
J Alfred Witjes, Harman Max Bruins, Albert Carrión, Richard Cathomas, Eva Compérat, Jason A Efstathiou, Rainer Fietkau, Georgios Gakis, Anja Lorch, Alberto Martini, La...> ;European Urology. 2024 Mar 15
1 citations
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Lerner, S., McConkey, D., Tangen, C., Meeks, J., Flaig, T., Hua, X., Daneshmand, S., Alva, A., Lucia, M., Theodorescu, D., Goldkorn, A., Milowsky, M., Choi, W., Bangs,...> ;Clinical Cancer Research. 2024 Jan 17
FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
Okato, A., Utsumi, T., Ranieri, M., Zheng, X., Zhou, M., Pereira, L., Chen, T., Kita, Y., Wu, D., Hyun, H., Lee, H., Gdowski, A., Raupp, J., Clark-Garvey, S., Manocha,...> ;The Journal of Clinical Investigation. 2024 Jan 16
2 citations
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pem...
Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, Daniel P Petrylak, Thomas W Flaig, Helen H Moon, Terence W Friedlander, Nataliya Mar, Rana R McKay, Sandy ...> ;Journal of Clinical Oncology. 2024 Apr 20
PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers.
Rathmell, W., Nimmagadda, S., Rowe, S., Oldan, J., Schroeder, J., Hoffman-Censits, J., Milowsky, M., Solnes, L., Gorin, M., Khandani, A.> ;PET Clinics. 2024 Apr 1
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
Miller, E., Eric J Miller, Tracy L Rose, Benjamin L Maughan, Matthew I Milowsky, Mehmet A Bilen, Bradley C Carthon, Xin Gao, Suthee Rapisuwon, Qianqian Zhao, Menggang ...> ;Cancer. 2024 May 1
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel, P., Sweis, R., Bupathi, M., Heath, E., Goodman, O., Hoimes, C., Milowsky, M., Davis, N., Kalebasty, A., Picus, J., Shaffer, D., Mao, S., Adra, N., Yorio, J., ...> ;European Urology Oncology. 2023 Dec 16
1 citations
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
Wolfgang Beckabir, Sara E Wobker, Jeffrey S Damrauer, Bentley Midkiff, Gabriela De la Cruz, Vladmir Makarov, Leah Flick, Mark G Woodcock, Petros Grivas, Marc A Bjurlin...> ;European Urology. 2024 Mar 1
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R Merchan, Rana R McKay, Daniel...> ;Future Oncology. 2024 Mar 1
Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications.
Kristin Weiss, Kathryn H Gessner, Alysen Demzik, Elizabeth Moreton, William Y Kim, Sara E Wobker, Tracy L Rose, Matthew I Milowsky, Marc A Bjurlin> ;Cancer Treatment and Research Communications. 2023 Jan 1
13 citations
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
J Alfred Witjes, Harman Max Bruins, Albert Carrión, Richard Cathomas, Eva Compérat, Jason A Efstathiou, Rainer Fietkau, Georgios Gakis, Anja Lorch, Alberto Martini, La...> ;European Urology. 2024 Jan 1
6 citations
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
Talal El Zarif, Amin H Nassar, Gregory R Pond, Tony Zibo Zhuang, Viraj Master, Bassel Nazha, Scot Niglio, Nicholas Simon, Andrew W Hahn, Curtis A Pettaway, Shi-Ming Tu...> ;Journal of the National Cancer Institute. 2023 Dec 6
1 citations
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, Ajjai Shivaram Alva, M Scott Lucia, David James McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I Milowsky, Ri...> ;European Urology. 2023 Sep 1
2 citations
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations.
Deborah B Doroshow, Peter H O'Donnell, Jean H Hoffman-Censits, Sumati V Gupta, Ulka Vaishampayan, Elisabeth I Heath, Philip Garcia, Qianqian Zhao, Menggang Yu, Matthew...> ;JCO Precision Oncology. 2023 Jul 1
16 citations
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig, Nataliya Mar, Helen H Moon, Terence W Friedlander, Rana R McKay, Mehmet...> ;Journal of Clinical Oncology. 2023 Sep 1
Cancer Associated Fibroblasts: An Understudied but Critical Component of the Tumor Microenvironment in Urothelial Cancer.
Sean Clark-Garvey, Jeffrey S Damrauer, Matthew I Milowsky> ;European Urology Oncology. 2023 Aug 1
10 citations
Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
Joshua J Meeks, Peter C Black, Matthew Galsky, Petros Grivas, Noah M Hahn, Syed A Hussain, Matthew I Milowsky, Gary D Steinberg, Robert S Svatek, Jonathan E Rosenberg> ;European Urology. 2023 Nov 1
Electronic cigarette, or vaping, product use-associated lung injury (EVALI) in a patient with testicular cancer: A case report.
Jacob Stein, Hannah E Kay, Jeremy Sites, Afsaneh Pirzadeh, Benny L Joyner Jr, Toni Darville, Marc A Bjurlin, Tracy L Rose, Ilona Jaspers, Matthew I Milowsky> ;Tumori. 2023 Dec 1
2 citations
Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research ...
Asia N Matthew-Onabanjo, Gabrielle Nortey, Richard S Matulewicz, Ramsankar Basak, Donna A Culton, Kimberly N Weaver, Kristalyn K Gallagher, Hung-Jui Tan, Tracy L Rose,...> ;Current Problems in Cancer. 2023 Jun 1
2 citations
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.
Dean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, Michael Schenker, Begoña P Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebret, Shahrokh F Shariat, Se...> ;Future Oncology. 2023 Feb 1
Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors.
Hartlee Johnston, Allison M Deal, Katherine P Morgan, Bianka Patel, Matthew I Milowsky, Tracy L Rose> ;Clinical Genitourinary Cancer. 2023 Jun 1
10 citations
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer.
Jeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, Mi Zhou, Elizabeth R Plimack, Matthew D Galsky, Petros Grivas, Noah M Hahn, Peter H O'Donnell, Gopa Iyer, David I Qu...> ;Nature Communications. 2022 Nov 4
66 citations
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R Merchan, Rana R McKay, Daniel...> ;Journal of Clinical Oncology. 2023 Jan 1
History of the Relationship Between Smoking and Bladder Cancer: A Public Health Perspective.
Kristin G Weiss, Richard S Matulewicz, Elizabeth Moreton, Kimberly A Shoenbill, Matthew I Milowsky, Tracy L Rose, William Y Kim, Adam O Goldstein, Marc A Bjurlin> ;Urology. 2023 Jan 1
1 citations
Does histologic subtype impact overall survival in observed T1a kidney cancers compared with competing risks? Implications for biopsy as a risk stratification tool.
Jamie Michael, Nermarie Velazquez, Audrey Renson, Hung-Jui Tan, Tracy L Rose, Chelsea K Osterman, Matthew Milowsky, Stella K Kang, William C Huang, Marc A Bjurlin> ;International Journal of Urology. 2022 Aug 1
Join now to see all

Lectures

Cost-effectiveness of CHOP in treating DLBCL in Malawi.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Carolina Cancer Experts Available for InterviewsMay 19th, 2023
Genetic Analysis of the Most Common Type of Bladder Cancer Yields Guidance on Treatment OptionsNovember 18th, 2022
Testicular Cancer Mapped Genomically and EpigenomicallyJune 13th, 2018
Join now to see all